LFST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LifeStance Health Group Inc (LFST) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown positive technical indicators and bullish analyst ratings, the company's financial performance has been mixed, with a significant drop in net income and EPS in the latest quarter. Additionally, the stock's short-term trend suggests a potential decline in the next week and month. Considering the investor's preference for long-term stability, it would be prudent to wait for more consistent financial growth and a clearer upward trend before investing.
The stock shows bullish technical indicators with a positive MACD histogram (0.0735), bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a pre-market price of $6.855 above the pivot level of $6.696. However, RSI_6 at 75.004 is in the neutral zone, and the stock's short-term trend indicates a potential decline of -2.24% in the next week and -3.81% in the next month.
Analysts have raised price targets consistently, with the highest target at $12, reflecting optimism about growth and productivity improvements.
Bullish technical indicators suggest short-term momentum.
Recent investments in AI tools and care-matching algorithms are expected to drive clinician productivity and growth.
Financial performance in the latest quarter showed a significant drop in net income (-264.06% YoY) and EPS (-250.00% YoY).
Short-term stock trend analysis indicates a potential decline in the next week and month.
No significant hedge fund or insider trading activity to suggest strong institutional confidence.
In Q4 2025, revenue increased by 17.43% YoY to $382.2 million, but net income dropped significantly by -264.06% YoY to $11.67 million, and EPS fell by -250.00% YoY to $0.03. Gross margin remained flat at 100%.
Analysts are optimistic with multiple firms raising price targets (e.g., Barclays to $9, UBS to $12, Canaccord to $10). The consensus is positive, citing strong growth potential, productivity improvements, and favorable reimbursement and utilization environments.
